Cargando…
Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Acute Ischemic Stroke
Ischemic stroke continues to be one of the most challenging diseases in translational neurology. Tissue plasminogen activator (tPA) remains the only approved treatment for acute ischemic stroke, but its use is limited to the first hours after stroke onset due to an increased risk of hemorrhagic tran...
Autores principales: | Lakhan, Shaheen E., Kirchgessner, Annette, Tepper, Deborah, Leonard, Aidan |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2013
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3615191/ https://www.ncbi.nlm.nih.gov/pubmed/23565108 http://dx.doi.org/10.3389/fneur.2013.00032 |
Ejemplares similares
-
Corrigendum: Matrix Metalloproteinases and Blood-Brain Barrier Disruption in Acute Ischemic Stroke
por: Lakhan, Shaheen E., et al.
Publicado: (2018) -
Inflammatory mechanisms in ischemic stroke: therapeutic approaches
por: Lakhan, Shaheen E, et al.
Publicado: (2009) -
Implications of MMP9 for Blood Brain Barrier Disruption and Hemorrhagic Transformation Following Ischemic Stroke
por: Turner, Renée J., et al.
Publicado: (2016) -
Severe Blood–Brain Barrier Disruption in Cardioembolic Stroke
por: Liu, Chang, et al.
Publicado: (2018) -
Bibliometric and visualization analysis of matrix metalloproteinases in ischemic stroke from 1992 to 2022
por: Gao, YiKun, et al.
Publicado: (2023)